One year of monopoly, three different verdicts: the fight over the Biotech Act’s flagship incentive

EU PERSPECTIVES - Expand, scrap, or keep it as it is? It depends on who you ask. A proposed extension of market protection for selected biotech medicines is dividing Brussels: industry is pushing for a wider scope, some MEPs want it removed entirely, while the European Commission is defending its current design. Read more

EFPIA warned that the EU's plan to extend the supplementary protection certificate (SPC) is too limited / Photo: Unsplash